Jiangsu Hengrui to Build $137 Million Biologic Drug Facility

Jiangsu Hengrui Medicine announced plans to spend $137 million building a new biologic drug manufacturing facility in Suzhou. The facility will be part of new Suzhou subsidiary, named Suncadia, which was recently established with $16 million in initial capital. Hengrui spends 10% of its $1.2 billion in revenues on new-drug R&D, and the company has formed several high-visibility innovative drug collaborations. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: // //